Literature DB >> 19801027

Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry).

Oliver Koeth1, Ralf Zahn, Anselm Kai Gitt, Timm Bauer, Claus Juenger, Jochen Senges, Uwe Zeymer.   

Abstract

Randomized clinical trials (RCTs) usually enroll selected patient populations that may not be representative for patients seen in everyday practice. Therefore, concerns have been raised regarding their external validity. For the present study we evaluated the MITRA Plus registry and included 20,175 patients with ST-elevation myocardial infarction. We defined RCT-ineligible patients as patients fulfilling >or=1 of the following criteria: age >or=75 years, prehospital delay >12 hours, prehospital cardiopulmonary resuscitation, cardiogenic shock, impaired renal function, and previous stroke. Those patients (n = 9,369, 46.4%) were compared to patients eligible for enrollment in RCTs (n = 11,806, 53.6%). Ineligible patients were older (p <0.0001), more often were women (p <0.0001), and more often had concomitant diseases (p <0.0001). Ineligible patients less often received early reperfusion therapy (p <0.0001), aspirin (p <0.0001), clopidogrel (p <0.0001), and statins (p <0.0001). Ineligible patients had a higher hospital mortality (20.1% vs 4.9%; p <0.0001) and a higher rate of nonfatal strokes (1.5% vs 0.4%, p <0.0001) compared to eligible patients. Early reperfusion therapy (thrombolysis and/or percutaneous coronary intervention [PCI]) in ineligible patients was associated with a significant decrease of hospital mortality (odds ratio 0.62, 95% confidence interval 0.49 to 0.79), with primary PCI being more effective than thrombolytic therapy (odds ratio 0.52, 95% confidence interval 0.41 to 0.65). In conclusion, about 50% of patients with ST-elevation myocardial infarction seen in clinical practice are usually excluded from RCTs. Hospital mortality in those patients is very high. Primary PCI improves the prognosis and is therefore the preferred reperfusion strategy in these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801027     DOI: 10.1016/j.amjcard.2009.05.054

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  [Registries of myocardial infarction in Germany. Consequences for drug therapy of patients with acute ST elevation myocardial infarction].

Authors:  U Zeymer; R Zahn; J Senges; A Gitt
Journal:  Internist (Berl)       Date:  2010-10       Impact factor: 0.743

Review 2.  Drug Treatment of STEMI in the Elderly: Focus on Fibrinolytic Therapy and Insights from the STREAM Trial.

Authors:  Peter R Sinnaeve; Thierry Danays; Kris Bogaerts; Frans Van de Werf; Paul W Armstrong
Journal:  Drugs Aging       Date:  2016-02       Impact factor: 3.923

3.  Euro Heart Survey 2009 Snapshot: regional variations in presentation and management of patients with AMI in 47 countries.

Authors:  Etienne Puymirat; Alex Battler; John Birkhead; Hector Bueno; Peter Clemmensen; Yves Cottin; Keith Aa Fox; Bulent Gorenek; Christian Hamm; Kurt Huber; Maddalena Lettino; Bertil Lindahl; Christian Müller; Alexander Parkhomenko; Susanna Price; Tom Quinn; Francois Schiele; Maarten Simoons; Gabriel Tatu-Chitoiu; Marco Tubaro; Christiaan Vrints; Doron Zahger; Uwe Zeymer; Nicolas Danchin
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-08-20

4.  External Validity of the HOPE-Trial: Hemiarthroplasty Compared with Total Hip Arthroplasty for Displaced Femoral Neck Fractures in Octogenarians.

Authors:  Sebastian Mukka; Pontus Sjöholm; Ghazi Chammout; Paula Kelly-Pettersson; Arkan S Sayed-Noor; Olof Sköldenberg
Journal:  JB JS Open Access       Date:  2019-06-07

5.  A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results.

Authors:  Tessa Kennedy-Martin; Sarah Curtis; Douglas Faries; Susan Robinson; Joseph Johnston
Journal:  Trials       Date:  2015-11-03       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.